BACKGROUND: It remains debated whether to include resting electrocardiogram (ECG) in the routine care of human immunodeficiency virus (HIV)-infected patients. METHODS: This analysis included 4518 HIV-infected patients (28% women and 29% blacks) from the Strategies for Management of Antiretroviral Therapy study, a clinical trial aimed to compare 2 HIV treatment strategies. ECG abnormalities were classified using the Minnesota Code. Cox proportional hazards analysis was used to examine the association between baseline ECG abnormalities and incident cardiovascular disease (CVD). RESULTS: More than half of the participants (n = 2325, or 51.5%) had either minor or major ECG abnormalities. Minor ECG abnormalities (48.6%) were more common than major ECG abnormalities (7.7%). During a median follow-up of 28.7 months, 155 participants (3.4%) developed incident CVD. After adjusting for the study-treatment arms, the presence of major, minor, and either minor or major ECG abnormalities was significantly predictive of incident CVD (hazard ratio [95% confidence interval]: 2.76 [1.74-4.39], P < .001; 1.58 [1.14-2.20], P = .006; 1.57 [1.14-2.18], P = .006, respectively). However, after adjusting for demographics, CVD risk factors, and HIV characteristics (full model), presence of major ECG abnormalities were still significantly predictive of CVD (1.83 [1.12-2.97], P = .015) but not minor or major abnormalities taken together (1.26 [0.89-1.79], P = .18; 1.25 [0.89-1.76], P = .20, respectively). Individual ECG abnormalities that significantly predicted CVD in the fully adjusted model included major isolated ST-T abnormalities, major prolongation of QT interval, minor isolated ST-T, and minor isolated Q-QS abnormalities. CONCLUSION: Nearly 1 in 2 of the HIV-infected patients in our study had ECG abnormalities; 1 in 13 had major ECG abnormalities. Presence of ECG abnormalities, especially major ECG abnormalities, was independently predictive of incident CVD. These results suggest that the ECG could provide a convenient risk-screening tool in HIV-infected patients.
BACKGROUND: It remains debated whether to include resting electrocardiogram (ECG) in the routine care of human immunodeficiency virus (HIV)-infected patients. METHODS: This analysis included 4518 HIV-infected patients (28% women and 29% blacks) from the Strategies for Management of Antiretroviral Therapy study, a clinical trial aimed to compare 2 HIV treatment strategies. ECG abnormalities were classified using the Minnesota Code. Cox proportional hazards analysis was used to examine the association between baseline ECG abnormalities and incident cardiovascular disease (CVD). RESULTS: More than half of the participants (n = 2325, or 51.5%) had either minor or major ECG abnormalities. Minor ECG abnormalities (48.6%) were more common than major ECG abnormalities (7.7%). During a median follow-up of 28.7 months, 155 participants (3.4%) developed incident CVD. After adjusting for the study-treatment arms, the presence of major, minor, and either minor or major ECG abnormalities was significantly predictive of incident CVD (hazard ratio [95% confidence interval]: 2.76 [1.74-4.39], P < .001; 1.58 [1.14-2.20], P = .006; 1.57 [1.14-2.18], P = .006, respectively). However, after adjusting for demographics, CVD risk factors, and HIV characteristics (full model), presence of major ECG abnormalities were still significantly predictive of CVD (1.83 [1.12-2.97], P = .015) but not minor or major abnormalities taken together (1.26 [0.89-1.79], P = .18; 1.25 [0.89-1.76], P = .20, respectively). Individual ECG abnormalities that significantly predicted CVD in the fully adjusted model included major isolated ST-T abnormalities, major prolongation of QT interval, minor isolated ST-T, and minor isolated Q-QS abnormalities. CONCLUSION: Nearly 1 in 2 of the HIV-infected patients in our study had ECG abnormalities; 1 in 13 had major ECG abnormalities. Presence of ECG abnormalities, especially major ECG abnormalities, was independently predictive of incident CVD. These results suggest that the ECG could provide a convenient risk-screening tool in HIV-infected patients.
Authors: U H Iloeje; Y Yuan; G L'italien; J Mauskopf; S D Holmberg; A C Moorman; K C Wood; R D Moore Journal: HIV Med Date: 2005-01 Impact factor: 3.180
Authors: W M El-Sadr; B Grund; J Neuhaus; A Babiker; C J Cohen; J Darbyshire; S Emery; J D Lundgren; A Phillips; J D Neaton Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Alan R Lifson; Waldo H Belloso; Cate Carey; Richard T Davey; Daniel Duprez; Wafaa M El-Sadr; Jose M Gatell; Daniela C Gey; Jennifer F Hoy; Eric A Krum; Ray Nelson; Daniel E Nixon; Nick Paton; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James Sampson; John Worley Journal: HIV Clin Trials Date: 2008 May-Jun
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Mihir Gupta; Christopher J Miller; Jason V Baker; Jason Lazar; Johannes R Bogner; Alexandra Calmy; Elsayed Z Soliman; James D Neaton Journal: Am J Cardiol Date: 2012-12-29 Impact factor: 2.778
Authors: Elsayed Z Soliman; Zhu-Ming Zhang; Lin Y Chen; Larisa G Tereshchenko; Dan Arking; Alvaro Alonso Journal: Am J Cardiol Date: 2016-10-08 Impact factor: 2.778
Authors: E Z Soliman; S Sharma; K Arastéh; D Wohl; A Achhra; G Tambussi; J O'Connor; J H Stein; D A Duprez; J D Neaton; A Phillips Journal: HIV Med Date: 2015-04 Impact factor: 3.180
Authors: Gerald S Bloomfield; Isabelle R Weir; Heather J Ribaudo; Kathleen V Fitch; Carl J Fichtenbaum; Laura E Moran; Roger Bedimo; Christopher de Filippi; Caryn G Morse; Jonathan Piccini; Markella V Zanni; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Pamela S Douglas Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Katherine Kentoffio; Alfred Albano; Bruce Koplan; Maggie Feng; Rahul G Muthalaly; Jeffrey I Campbell; Ruth Sentongo; Russell P Tracy; Robert Peck; Samson Okello; Alexander C Tsai; Mark J Siedner Journal: Glob Heart Date: 2019-10-01
Authors: Katherine C Wu; Long Zhang; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Elsayed Z Soliman; Wendy S Post Journal: Heart Date: 2018-10-26 Impact factor: 5.994
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: Farah Z Dawood; Mollie P Roediger; Greg Grandits; Dery Miller; Martin Fisher; Zhu-Ming Zhang; Sally Hodder; Jennifer F Hoy; Jens D Lundgren; James D Neaton; Elsayed Z Soliman Journal: J Electrocardiol Date: 2013-12-04 Impact factor: 1.438
Authors: Farah Z Dawood; Faraaz Khan; Mollie P Roediger; Zhu-Ming Zhang; Shobha Swaminathan; Hartwig Klinker; Jennifer Hoy; Jens D Lundgren; James D Neaton; Elsayed Z Soliman Journal: Am J Cardiol Date: 2012-10-09 Impact factor: 2.778
Authors: Elsayed Z Soliman; Mollie P Roediger; Daniel A Duprez; Hernando Knobel; Richard Elion; James D Neaton Journal: BMJ Open Date: 2013-03-06 Impact factor: 2.692